Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961407 | 0.76 | CYP2A6 (0.69) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL27803006 | 0.72 | CYP2A6 (0.50) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL2103758 | 0.70 | BACE1 (0.47) | CYP2A6 | |
| SCHEMBL340071 | 0.70 | LOXL2 (0.47) | LOXL2AGXTSLC5A2 | |
| SCHEMBL10915640 | 0.70 | ADRA1D (0.54) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL6344255 | 0.70 | CYP2A6 (0.60) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL7338114 | 0.70 | CYP2A6 (0.60) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL4821398 | 0.69 | ADRA1D (0.47) | ADRA1D | |
| SCHEMBL24852615 | 0.69 | CYP2A6 (0.47) | ADRA1DCYP2A6ADRB2ASIC3LOXL2 | |
| SCHEMBL349903 | 0.69 | CYP11B1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370533-B1 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| WO-2008079720-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATNG CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079728-A2 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ADRA2B, ADRA1B, ADRB1 | ADRA1D 12/4885CYP2A6 764/4885ADRB2 5/4885 |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, GPBAR1, MLNR | ADRA1D 36/4885CYP2A6 972/4885ADRB2 11/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA1D 140/4885CYP2A6 1020/4885ADRB2 61/4885 |
| US-20080153927-A1 | ALPHA-2B RECEPTOR AGONIST AND RELAXANT COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, ADRA1B, CCKBR | ADRA1D 19/4885CYP2A6 1359/4885ADRB2 4/4885 |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | HTR2B, HTR4, HTR3B | ADRA1D 37/4885CYP2A6 1031/4885ADRB2 32/4885 |
| US-20080153874-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | ADRA1D 140/4885CYP2A6 1020/4885ADRB2 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.